Two of the three recently priced public companies have fallen below their share prices, demonstrating fears of the IPO market not being very friendly since the downfall of WeWork. Though the biotechnology sector is less sensitive to market volatility due to the specialized investor base, recent offerings from this sector have shown that even drug companies are starting to struggle in the current market environment.
The German biotechnology firm BioNTech SE (NASDAQ: BNTX) priced on October 10 at $15 per share with 10 million shares raised. The firm had raised $150 million, but in its first few days of trading struggled to debut.
HBT Financial, Inc. (NASDAQ: HBT), the parent company of Heartland Bank & Trust or Illinois' second-largest privately held bank, priced at $16 per share with 8.3 million shares on October 11, with a raised offering amount of $132,800,000. The financial firm took a bit of the dive in its first few days of trading, but has been steadily increasing in daily trading.
VIR Biotechnology, Inc. (NASDAQ: VIR) priced at $20 per share with 7,142,858 shares on October 11. The biotechnology firm had an offering amount of $142,857,160. The SoftBank (OTCMKTS: SFTBY)-backed firm fell as much as 28% in of the the worst market debuts in recent months.
BellRing Brands, Inc., with 30 million shares, is set...